ArticleJournal of radiation research2026
18F-BPA as a surrogate tracer for BPA in BNCT: comparative analysis of transport mechanisms and biodistribution.
Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Moving beyond SUVJapanese journal of radiology · 2026Article
- In reply: Moving from maximum uptake to volumetric heterogeneous dose coverage in BNCT.Japanese journal of radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
4-Borono-L-phenylalanine (BPA) is a key 10B carrier used in boron neutron capture therapy (BNCT), while its PET tracer analogue, 4-borono-2-18F-fluoro-L-phenylalanine (18F-BPA), enables non-invasive visualization of tumour boron uptake. Since BNCT efficacy depends on precise tumour boron accumulation, we evaluated whether 18F-BPA mirrors BPA's transport and biodistribution. In vitro, BPA exhibited a highly consistent uptake profile with its non-radioactive fluorinated analogue, 2-19F-4-borono-L-phenylalanine (19F-BPA), across nine cancer cell lines (r = 0.9455, P < 0.001) and tri-iodothyronine (T3)-mediated LAT-1 inhibition markedly reduced the uptake of both BPA and 19F-BPA. In vivo, BPA and 18F-BPA showed predominant accumulation in the kidneys and pancreas in Sprague-Dawley rats, with substantially lower levels detected in other organs. Importantly, in tumour-bearing mice, the time-concentration curve of BPA and the time-activity curve of 18F-BPA in tumours were found to be highly consistent, and showed a corresponding relationship between BPA concentration and 18F-BPA activity in terms of accumulation in tumour, blood, and muscle (r = 0.9623, P < 0.0001). Collectively, these findings confirm that BPA and 18F-BPA not only share LAT-1-mediated transport mechanisms, but also exhibit similar pharmacokinetics and tumour-specific accumulation. This substantiates the use of 18F-BPA as a reliable surrogate for visualizing BPA biodistribution and optimizing patient-specific BNCT treatment planning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.